Navigating Policy and Utilization Management in Oncology: Aligning Evidence with Access

Panelists discuss how national policy reforms are reshaping oncology care by balancing affordability efforts with the need to preserve access and innovation.

Panelists discuss how aligning evolving payer policies with real-world oncology practice is key to sustaining timely and equitable patient access.

Panelists discuss how PBMs shape oncology access and stress the need for transparency to align financial control with clinical priorities.

Panelists discuss how utilization management policies can delay oncology care and call for reforms that better align oversight with clinical evidence.

Panelists discuss how step edits hinder timely cancer treatment and urge policies that prioritize evidence-based access over cost-driven sequencing.

Panelists discuss how outdated coverage models lag behind oncology innovation, calling for dynamic policies that reflect evolving clinical evidence.

Panelists discuss how payer coverage restrictions often conflict with NCCN guidelines for BTK inhibitor therapies in CLL, impeding evidence-based care.

Panelists discuss how outdated coverage decisions can worsen outcomes and increase costs by delaying access to safer, evidence-supported BTK inhibitor therapies.

Panelists discuss how integrating real-world evidence into coverage frameworks can enhance decision-making and align payer policies with actual patient outcomes.

Panelists discuss how payers should interpret black box warnings with clinical context to prevent unnecessary restrictions on safe, evidence-based treatments.

Panelists discuss how utilization management limits clinical autonomy and advocate for reforms that preserve shared, patient-centered decision-making.

Panelists discuss how integrating safety and access considerations into oncology policy can create more equitable, patient-centered coverage models.

Panelists discuss how the IRA’s drug pricing reforms aim to improve affordability but may influence future oncology innovation.

Panelists discuss how IRA-driven BTK inhibitor price changes could shift payer preferences, necessitating vigilance to preserve clinical integrity in treatment selection.

Panelists discuss how evolving policy reforms will reshape oncology research by balancing innovation, access, and affordability.